Robert A. Scott - 23 Oct 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 23 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Oct 2026, 16:20:09 UTC
Prior SEC filing: 25 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, as Attorney-in-Fact for Robert A. Scott

Filing notes and source

Key filing fact

Robert A. Scott filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 28 Oct 2026.

Key facts

This page summarizes Robert A. Scott's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Oct 2026, 16:20.

Change

Previous filing in this sequence was filed on 25 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001248520 Primary reporting owner

SCOTT ROBERT A

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Robert A. Scott
Signature date: 28 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value
Shares: +2,819
Change %
Price: $0.000000^*
Shares after: 2,819
Date: 23 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +20,507
Change %
Price: $0.000000^*
Shares after: 20,507
Date: 23 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,507
Exercise price: $31.20
Footnotes: F2

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +8,663
Change %
Price: $0.000000^*
Shares after: 8,663
Date: 23 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,663
Exercise price: $31.20
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.

Footnote F2

1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of October 23, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.

Footnote F3

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.